Background In autologous chondrocyte implantation (ACI), the periosteum patch which is sutured over the cartilage defect has been identiWed as a major source of complications such as periosteal hypertrophy. In the present retrospective study, we compared midterm results of Wrstgeneration ACI with a periosteal patch to second generation ACI using a biodegradable collagen Xeece (BioSeed-C) in 82 patients suVering from chronic posttraumatic and degenerative cartilage lesions of the knee. Methods Clinical outcome was assessed in 42 patients of group 1 and in 40 patients of group 2 before implantation of the autologous chondrocytes and at a minimum follow-up of 2 years using the ICRS score, the modiWed Cincinnati score and the Lysholm score. Results Although patients treated with BioSeed-C had more previous surgical procedures on their respective knees, highly signiWcant improvements (P < 0.001) were assessed in both groups at comparable outcome levels: the ICRS score improved from grade D (poor) preoperatively to grade C (fair); the modiWed Cincinnati knee score from 3.26 to 6.4 (group 1) and 3.3 and 6.88 (group 2). Lysholm score improved from 33 to 70 points (group 1) and from 47 to 78 points (group 2), respectively. Revision surgery was due to symptomatic periosteal hypertrophy (n = 4), graft failure (n = 3), plica syndrome (n = 2) synovectomy (n = 1) (group 1); and graft failure (n = 2), debridement (n = 1), synovectomy (n = 2) (group 2). Conclusion These results suggest that BioSeed-C is an equally eVective treatment option for focal degenerative chondral lesions of the knee in this challenging and complex patient proWle.
Introduction
The treatment of cartilage defects represents a common, complex and multifaceted task for orthopaedic surgeons; particularly, in young patients suVering from large cartilage defects, there are only limited conservative and surgical treatment options. Thus, several eVorts to restore articular cartilage were undertaken [4, 11, 14, 20, 23, 38] . However, these cartilage repair techniques provide only limited durability of the repair tissue [29] or suitable for small defects only [6] . In contrast, autologous chondrocyte implantation (ACI) introduced in 1994, lacks these disadvantages, but provides hyalinelike cartilage [4, [35] [36] [37] .
Autologous chondrocyte implantation has been recommended as the treatment of choice for symptomatic cartilage defects larger than 2 cm [2] and for failed cartilage repair procedures and more than 10,000 patients worldwide have been treated with ACI already [26] . Encouraging short to midterm results of ACI were reported from case series [7, 9, 24, 25, 33, 39] , while randomised clinical trials could not clearly demonstrate superiority of ACI compared with either microfracture or osteochondral cylinder transplantation [3, 12, 13, 17, 18] . First-generation ACI involves harvesting a periosteal Xap from the tibia that later has to be Wxed to the surrounding cartilage requiring a contained cartilage lesion. Application in some regions of the knee may thus be delicate or even impossible. Notably, the periosteal Xap covering the defect has been identiWed as a potential source of complications resulting in reoperations in up to 25% of the patients [19, 24, 27, 28, 37] . To eliminate this signiWcant disadvantage, to prevent chondrocytes from dediVerentiation, to improve adhesion and to facilitate handling, ACI has been reWned through the development of bioresorbable matrices (e.g., MACI, BioSeed-C). With these grafts, it is no longer necessary to have a stable cartilage rim surrounding the defect and non-contained lesions can be addressed as well as contained lesions. Addressing defects on the medial or lateral femoral condyle that are smaller than 2 cm [2] , BioSeed-C can be implanted arthroscopically [8] .
BioSeed-C is now frequently applied to a signiWcant patient population. Theoretically, the advantages of this technique would make it a better choice for the treatment of full-thickness cartilage lesions of the knee outclassing standard periosteum ACI. However, no study has compared BioSeed-C to the standard method of periosteum ACI yet. Therefore, orthopaedic surgeons cannot be sure of whether they deprive their patients of a potentially better articular cartilage repair if keeping at periosteum ACI. To determine which of the two techniques should be chosen to ensure best treatment results, to optimise the outcome and the beneWt for the patients suVering from full-thickness cartilage lesions of the knee and to assess typical complications of both techniques, we performed a retrospective study to evaluate and to compare the clinical outcomes of standard ACI to ACI using a biodegradable polymer-Xeece.
Materials and methods
In this clinical non-randomised retrospective study, 82 patients (42 women, 40 men) meeting the following criteria were included: (1) clinical and radiographic [16] focal full-thickness cartilage lesions of the knee on the medial or lateral femoral condyle, patella or trochlea; (2) lesion grades III-IV in the Outerbridge classiWcation [34] ; (3) symptom-like pain or dysfunction of the knee joint and (4) given patient's oral consent following adequate information about mode of data acquisition, processing, analysis, interpretation and publication, according to regional guidelines.
Patients fulWlling at least one of the following criteria were not included in this study: (1) severe osteoarthritis; (2) diVuse tricompartmental degeneration; (3) multiple small lesions <1 cm [2] ; (4) bilateral chondrocyte implantation; (5) age over 65 years; (6) presence of active infection; (7) injuries or aZictions of regions other than the knee; (8) gravity; (9) neoplasms; (10) radicular pain; (11) paralysis; (12) psychiatric diseases and (13) Wbromyalgia.
Between March 1997 and October 2004, 82 patients were treated with ACI for full-thickness cartilage lesions of the knee in one hospital. They formed two groups: group 1 was treated with standard periosteum ACI and group 2 with ACI using a biodegradable Xeece (BioSeed-C). There were 29 men and 13 women in group 1 and 22 men and 18 women in group 2. Mean defect size was 6.38 cm² (2-17.5) in group 1 and 4.6 cm² (2-15) in group 2 (P < 0.001). Average age was 34 (16-53) and 36 years (17-64), respectively. In both groups, defects were mainly situated on the medial femoral condyle (group 1: n = 29, group 2: n = 27). Mean follow-up of the periosteum ACI group was 36 months (24-63), of the BioSeed-C group 24 months (24 months). All but three patients of group 1 had at least one previous surgical procedure on the knee, with a mean of 1.94 (0-4). In group 2, all patients had previous surgical procedures of the knee with a mean of 3.35 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , including meniscectomies (group 1: n = 20, group 2: n = 20), reconstructions of the anterior cruciate ligament (group 1: n = 10, group 2: n = 12) and cartilage repair procedures like abrasion arthroplasty (group 1: n = 10, group 2: n = 0), microfractures and drillings (group 1: n = 17, group 2: n = 13), respectively. In patients with the disruption of the anterior cruciate ligament, ACL reconstruction is required and was performed together with ACI; so was done with malalignment. More detailed information about the study cohorts is given in Table 1 .
ICRS score [15] , Lysholm score [21] , Cincinnati score [31, 32] and the modiWed Cincinnati knee score [30] were used for evaluation of outcome. Data acquisition was performed by an independent investigator. Clinical evaluation and scoring were done preoperatively and at follow-up. To calculate levels of signiWcance, the paired and unpaired Wilcoxon-rank sum test was done with SPSS for Windows Version 11.0 (SPSS, Chicago, IL, USA).
Table 1
Characteristics of the two patient groups compared in the present study For both procedures, periosteum ACI and BioSeed-C, the cartilage defect was assessed arthroscopically for deWnite indication to ACI. Approximately, 250 mg of articular cartilage was taken as a biopsy from a lesser or non-weight bearing region of the knee as the linea terminalis or the intercondylar notch. The biopsy was placed in transport container provided by the commercial cell culturing company and sent to the respective company's cell culturing facility (Genzyme Biosurgery, Cambridge, MA, USA; Biotissue Technologies, Freiburg, Germany). There, chondrocytes were expanded in vitro. For conventional ACI, these chondrocytes were brought into a suspension at for later injection. For BioSeed-C, the chondrocytes were rearranged three dimensionally in Wbrin and a polymer-based scaVold of polyglycolic/polylactic acid (polyglactin, vicryl) and polydioxanone. The implantation of the cultured autologous chondrocytes was performed at a date according to the laboratory guidelines. Under general or local anaesthesia and antibiotic prophylaxis, a medial or lateral arthrotomy was performed preparing the cartilage defect in a tourniquet-controlled bloodless Weld. The cartilage lesion was carefully debrided back to healthy cartilage building a stable rim.
For periosteum ACI, a template was Wtted to defect size and periosteum was harvested from the lateral aspect of the tibia using this template. This periosteal Xap was Wtted to defect size and sutured into the defect cambium layer down (Vicryl 6-0) leaving a gap for the injection of the cultured chondrocytes ( Fig. 1 b, arrowhead) . The rim was sealed with Wbrin glue. The chondrocyte suspension was injected under the periosteal Xap and the Xap was Wnally secured and sealed with Wbrin glue and a Wnal suture.
BioSeed-C is a resorbable composite material consisting of polyglaction 910 and poly-p-dioxanone collagen Xeece seeded with autologous chondrocytes in a three-dimensional matrix. It contains 20 £ 10 6 cells/cm 3 Wxed with approximately 5-7 mg Wbrin adhesive and will be resorbed after 2-3 months. For the BioSeed-C procedure, the defect was debrided to a rectangular shape down to the subchondral bone using a sharp curette (Fig. 2d) . A template was taken and the Xeece Wtted to size. Using a resorbable thread, the graft (Fig. 2a) was armed with a double-knot loop at each corner (Vicryl 2-0). One threefold knot approximately 1 cm from the edge secures the sling (Fig. 2b ). An additional knot approximately 1 cm out moors the sling and serves as a pulley. Using k-wires (1.7 mm, 35 cm long with eye), four drill holes on the corners of the defect were made to Wx the implant transosseously (Fig. 2c) . Firm action on the pulleys guided the knots into the transosseous drill holes at the corners of the defect (Fig. 2d) . The pulley slings were cut close to their dermal exit (Fig. 2e) .
For both procedures, arthrotomy was closed under careful haemostasis. For postoperative management, continuous passive motion machines were used starting the Wrst postoperative day. Range of motion initially was limited to 40° of Xexion and was increased in stages of 5°-10° per day limited to 90° of Xexion. The operated knee was unloaded for 6 weeks with approximately 15% of the body weight. Physiotherapy was prescribed individually. Starting the seventh postoperative week, load was increased gradually and speciWc isometric strengthening exercises were performed. Light exercise such as walking or cycling was Fig. 1 Periosteum ACI: the cartilage defect was debrided back to healthy cartilage (left). A periost patch harvested from the tibia was sutured into the defect cambium layer down. On the upper left side, one suture was skipped (arrow) which will be done later to allow injection of the autologous chondrocyte suspension (right) allowed after the sixth postoperative month and return to contact sports was not recommended before 12 months postoperatively.
Results
Intraoperatively, no loosening, ablation or derangement of either transplant occurred. No knee joint infection and no allergic reaction occurred in either group. Postoperatively, neither an extension lag nor a Xexion deWcit could be observed. One patient of the BioSeed-C group had a moderate eVusion at follow-up, but not other problems and did well later on. The rate of follow-up in the periosteum group was 100%. In the BioSeed-C group, the grafts of one patient were removed in a peripheral institution due to soft regeneration tissue after 9 months. This patient was registered as a treatment failure. Another patient developed paraplegia during follow-up and, therefore, was excluded from the study. One patient was lost to follow-up due to unknown address.
At follow-up, mean scores signiWcantly increased in both groups compared with baseline: in the periosteal group, the ICRS score improved from grade D (poor) preoperatively to grade C (fair) post-op (P < 0.0001) with a range from grade A (excellent) to grade D (poor) (Fig. 3a) . The modiWed Cincinnati knee score improved from 3.26 to 6.44 (patient) (P < 0.0001) and from 3.36 to 6.88 (physician) (P < 0.0001) (Fig. 3b, c) . Mean Lysholm score improved from 33 to 70 points (P < 0.0001) (Fig. 3d) .
In BioSeed-C group, like in the periosteum group, the ICRS score improved from grades D to C as well (P < 0.0001) (Fig. 3a) . The modiWed Cincinnati knee score increased from 3.3 to 6.4 (patient) (P < 0.0001) and from 4.9 to 6.5 (physician) (P < 0.0001) (Fig. 3b, c) . Mean Lysholm score enhanced from 47 to 78 points (P < 0.0001) (Fig. 3d) . There was no signiWcant diVerence between groups 1 and 2 in the ICRS score rating (P = 1) and in the Lysholm score (P = 0.065). In the overall rating of the modiWed Cincinnati knee score (patient), the diVerence between groups was not statistically signiWcant (P = 0.39). However, the physician rating was signiWcantly better in the periosteum group (P = 0.033).
In the periosteum group, 10 patients required revision surgery, due to symptomatic periosteal hypertrophy (n = 4) or graft failure (n = 3), plica syndrome (n = 2) and synovectomy (n = 1).
In the BioSeed-C group, reoperations were necessary and regarded as directly related to ACI in Wve patients. One patient underwent graft removal in a peripheral institution and was thus registered as a treatment failure. Two patients had a synovectomy and one patient had a debridement and one a total knee replacement, respectively.
Discussion
The aim of the present study was to compare the clinical outcome of standard periosteum ACI to BioSeed-C (ACI using a biodegradable Xeece) in patients with focal degenerative cartilage defects of the knee. Patients of both treatment groups showed highly signiWcant increases in the respective scores used for outcome measurement The graft is armed with vicryl sutures at every corner which serve as a pulley (b) and are Wxed transosseously using 1.7-mm-k-wires in an insideout technique (c); that way, the graft is smoothly Wtted into the defect (d) and securely Wxed in a press-Wt technique (e) demonstrating major improvements in activities of daily living, ability to work and in sports. Patients treated with periosteal ACI required twice as many reoperations as patients treated with BioSeed-C. In the ICRS score, the patient rating of the modiWed Cincinnati knee score and the Lysholm score, the outcome was comparable between the periosteum and the BioSeed-C group. However, in the objective and strict ICRS score and in the patient rating of the modiWed Cincinnati knee score, patients treated with periosteum ACI scored slightly, but not signiWcantly better, whereas in the Lysholm score, it was vice versa. In contrast, in the physician's rating, BioSeed-C patients scored slightly worse than periosteum patients, because of better baseline ratings.
The patients of the two groups compared in this study diVered in defect size, number of previous or concomitant surgical procedures and length of the postoperative followup period. This may inXuence the results. However, the impact of this potential eVect is unknown. The group treated with conventional ACI had larger defects and longer follow-up. However, a direct comparison of the two groups may be inappropriate, as there were signiWcantly more previous surgical procedures in the group treated with BioSeed-C.
When compared with case series, randomised studies evaluating ACI versus other cartilage repair surgeries as reported previously are favourable [3, 12, 13, 17, 18] . A recent systematic review comparing ACI and osteochondral autograft transfer with each other with one another and with traditional abrasive techniques demonstrated no clear superiority of ACI over microfracture [22] in line with the Wndings published by other authors [17, 18] . However, in another study, ACI showed a superior cartilage regenerate than microfracture at same clinical short-term results [39] .
When comparing the two ACI methods, the present study shows that these are equally eVective. Advantages of the BioSeed-C techniques comprise less morbidity, as no periosteum has to be harvested and the option of arthroscopical implantation. Defects of the femoral condyles can be addressed arthroscopically depending on lesion size and location which is associated with faster recovery after surgery and with better cosmetical results. Further advantages of BioSeed-C, are that it is easier to apply, is more stable than the periosteum cartilage transplant and triggers less second look surgeries, because there can be no periosteum hypertrophy. This may partly be due to the lacking periosteum hypertrophies frequently causing reoperations in patients treated with ACI using periosteum. ACI involves an open technique with inherent disadvantages such as adhesions and prolonged recovery. Therefore, an arthroscopical approach to ACI as published previously is desirable and could potentially reduce postoperative morbidity [8] . The authors believe that this is the Wrst study comparing standard ACI to a 3D Xeece technique (BioSeed-C), representing a non-randomised retrospective, comparative study with at least 40 patients in each group. However, the outcome of this study should be interpreted with care and statistical eVects associated with small numbers of patients may be considered.
First-generation tissue engineering grafts such as periosteum ACI have been demonstrated to be an appropriate therapy for the regeneration of posttraumatic defects [5, 10] . However, second generation cartilage tissue engineering grafts using various matrices were recently considered to be technically more attractive. For instance, in a series of 47 cartilage defects, similar outcomes were obtained clinically as well as histologically [1] . In a multicenter study evaluating Hyalograft C, which consists of autologous chondrocytes embedded in a derivative of hyaluronic acid, more than 90% of patients showed improvements of the ICRS score [23] . Clinical assessment as done by the Meyers score, the Lysholm score and in the ICRS scores was improved in a prospective study investigating 5-year results of matrix associated ACI [2] . In summary, we regard the outcome of this study as a decent treatment result for this diYcult and highly demanding patient proWle, particularly because patients treated with BioSeed-C had the same outcome levels, e.g., in kneerelated performance and quality of life as the patients treated with periosteum ACI, although they have had more surgeries on their knees before.
Concerning its advantages in comparison to periosteum ACI, we conclude that BioSeed-C is equally eVective as periosteum ACI.
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